coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAF(V600) mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Transl Med
Asıl Yazarlar: Ascierto, Paolo A, McArthur, Grant A, Dréno, Brigitte, Larkin, James, Liszkay, Gabriella, Maio, Michele, Mandala, Mario, Demidov, Lev, Stroyakovskiy, Daniil, Thomas, Luc, de la Cruz-Merino, Luis, Atkinson, Victoria, Dutriaux, Caroline, Garbe, Claus, Chang, Ilsung, Hack, Stephen P, Ribas, Antoni
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2015
Konular:
Oral Presentation
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4315268/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-13-S1-O4
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller